Pamidronate treatment for hypercalcemia in an infant receiving parenteral nutrition

Pharmacotherapy

Volumn 24, Issue 7 I, 2004, Pages 939-944

  Bryowsky, Jason J ^a   Bugnitz, Mark C ^b   Hak, Emily B ^a,b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LE BONHEUR CHILDREN S HOSPITAL   (United States)

^c Ctr Pediat Pharmacokin/Therapeut   (United States)

Author keywords

Hypercalcemia; Pamidronate; Parenteral nutrition; Pediatric patients

Indexed keywords

ALENDRONIC ACID; AMPHOTERICIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CASPOFUNGIN; CEFTAZIDIME; CLINDAMYCIN; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ETIDRONIC ACID; FLUCONAZOLE; FUROSEMIDE; HYDROCORTISONE; MEROPENEM; NORADRENALIN; PAMIDRONIC ACID; TOBRAMYCIN; VANCOMYCIN; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; ANASARCA; ANTIBIOTIC THERAPY; ARTICLE; BONE GROWTH; CALCIUM BLOOD LEVEL; CANDIDIASIS; CASE REPORT; CHILD; DIURETIC THERAPY; DRUG EFFECT; ENDOCARDITIS; ENTERIC FEEDING; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INFANT; INFANT NUTRITION; INFECTION; KIDNEY FAILURE; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN INTENSIVE CARE; NEWBORN SEPSIS; PARENTERAL NUTRITION; SEIZURE; SMALL INTESTINE RESECTION; TREATMENT OUTCOME; URTICARIA;

DIPHOSPHONATES; HUMANS; HYPERCALCEMIA; INFANT, NEWBORN; MALE; PARENTERAL NUTRITION;

EID: 3042696714     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.9.939.36103     Document Type: Article

References (40)

1. Novartis Pharmaceuticals. Aredia (pamidronate) prescribing information. East Hanover, NJ; 2003.
2. Khan N, Licata A, Rogers D. Intravenous bisphosphonate for hypercalcemia accompanying subcutaneous fat necrosis: a novel treatment approach. Clin Pediatr 2001;40:217-19.
3. Attard TM, Dhawan A, Kaufman SS, Collier DS, Langnas AN. Use of disodium pamidronate in children with hypercalcemia awaiting liver transplantation. Pediatr Transplant 1998;2:157-9.
4. Pradhan M, Leonard MB. Calcium-free hemodialysis for hypercalcemia of malignancy in a newborn. Pediatr Nephrol 2003;18:474-6.
5. Chien YH, Chu SY, Hsu CC, Hwu WL. Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. J Inherit Metab Dis 2002;25:593-5.
6. Rice AM, Rivkees SA. Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn. J Pediatr 1999;134:349-51.
7. Bereket A, Erdogan T. Oral bisphosphonate therapy for vitamin D intoxication of the infant. Pediatrics 2003;111:899-901.
8. Duke JL, Jones DP, Frizzell NK, Chesney RW, Hak EB. Pamidronate in a girl with chronic renal insufficiency dependent on parenteral nutrition. Pediatr Nephrol 2003;18:714-17.
9. Chakravarty K, Merry P, Scott DGI. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone. J Rheumatol 1994;21:2118-21.
10. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998;87:64-8.
11. Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997;131:662-6.
12. Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A. Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 1998;157:261-2.
13. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52.
14. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J. Efficacy of low-dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001;15:529-33.
15. Kodama H, Kubota K, Abe T. Osteogenesis imperfecta: are fractures and growth hormone treatment linked [letter]? J Pediatr 1998;132:559-60.
16. Roldan EJA, Pasqualini T, Plantalech L. Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength: report of two patients. J Pediatr Endocrinol Metab 1991;12:555-9.
17. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003;111:1030-6.
18. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003;88:986-92.
19. Bembi B, Agosti E, Boehm P, Nassimbeni G, Zanatta M, Vidoni L. Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3. Acta Paediatr 1994;83:122-4.
20. Lala R, Matarazzo P, Bertelloni S, Buzi F, Rigon F, De Sanctis C. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. Acta Paediatr 2000;89:188-93.
21. Zacharin M, O'Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune-Albright syndrome. J Pediatr 2000;137:403-9.
22. Zumkeller W, Jassoy A, Lebek S, Nagel M. Clinical, endocrinological and radiography features in a child with McCune-Albright syndrome and pituitary adenoma. J Pediatr Endocrinol Metab 2001;14:553-9.
23. Boudailliez BR, Pautard BJ, Sebert JL, Kremp O, Piussan CX. Leukaemia-associated hypercalcemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate. Pediatr Nephrol 1990;4:510-11.
24. De Schepper J, de Pont S, Smitz J, De Coster D, Schots R, Otten J. Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcemia in a 11-year-old boy. Eur J Pediatr 1999;158:765-8.
25. Kutluk MT, Hazar V, Akyuz C, Varan A, Buyukpamukcu M. Childhood cancer and hypercalcemia: report of a case treated with pamidronate. J Pediatr 1997;130:828-31.
26. Lteif AN, Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics 1998;102:990-3.
27. Hoekman K, Papapoulos SE, Peters ACB, Bijvoet OLM. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 1985;61:952-6.
28. Shaw NJ, Boivin CM, Crabtree NJ. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000;83:143-5.
29. Brumsen C, Hamdy NAT, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine 1997;76:266-83.
30. Sellers E, Sharma A, Rodd C. The use of pamidronate in three children with renal disease. Pediatr Nephrol 1998;12:778-81.
31. Pelegano JF, Rowe JC, Carey DE, et al. Simultaneous infusion of calcium and phosphorus in parenteral nutrition for premature infants: use of physiologic calcium/phosphorus ration. J Pediatr 1989;114:115-19.
32. Prestridge LL, Schanler RJ, Shulman, Burns PA, Laine LL. Effect of parenteral calcium and phosphorus therapy on mineral retention and bone mineral content in very low birth weight infants. J Pediatr 1993;122:761-8.
33. Guzman JM, Jaraba MP, de la Torre MJ, et al. Parenteral nutrition and immature neonates: comparative study of neonates weighing under 1000 and 1000-1250 g at birth. Early Hum Dev 2001(suppl);65:S133-44.
34. Zlotkin SH, Buchanan BE. Amino acid intake and urinary zinc excretion in newborn infants receiving total parenteral nutrition. Am J Clin Nutr 1999;48:330-4.
35. Seidner DL, Licata A. Parenteral nutrition-associated metabolic bone disease: pathophysiology, evaluation, and treatment. Nutr Clin Pract 2000;15:163-70.
36. Fleisch H. Bisphosphonates: mechanisms of action. Endocrine Rev 1998;19(1):80-100.
37. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelan F. Renal failure associated with intravenous diphosphonates. Lancet 1983;(1):471.
38. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-63.
39. Srivastava, T, Alom U. Bisphosphonates: from grandparents to grandchildren. Clin Pediatr 1999;38:687-702.
40. Shoemaker LR. Expanding role of bisphosphonate therapy in children. J Pediatr 1999;134:264-7.